BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4//
BEGIN:VEVENT
UID:20250625T220404EDT-2695FXAP3D@132.216.98.100
DTSTAMP:20250626T020404Z
DESCRIPTION:Cardiovascular benefits and potential side effects of SGLT2 inh
 ibitors\, a new class of anti-hyperglyceamic drugs\n\nAnita Layton (Waterl
 oo)\n	Tuesday March 5\, 12-1pm\n	Montreal Neurological Institute\, deGrandpr
 e Communications Centre\n	\n	Abstract: Computational modeling can be used to
  reveal insights into the mechanisms and potential side effects of a new d
 rug. Here we will focus on diabetes\, which affects 1 in 10 people in Nort
 h America. Specifically\, we are interested in a class of relatively novel
  drug treatment\, the SGLT2 inhibitors (sodium-glucose co-transporter 2 in
 hibitors). E.g.\, Dapagliflozin\, Canagliflozin\, and Empagliflozin. SGLT2
  inhibitors targets the kidney\, specifically\, the proximal convoluted tu
 bule which under euglycemic conditions reabsorbs all the filtered glucose.
  We conduct simulations to better understand (1) the mechanisms underlying
  the blood pressure lowering effects observed in clinical trials\, and (2)
  any side effect these drugs may have on our kidneys.\n
DTSTART:20190305T170000Z
DTEND:20190305T180000Z
LOCATION:deGrandpre Communications Centre\, Montreal Neurological Institute
 \, CA\, QC\, Montreal\, H3A 2B4\, 3801 rue University
SUMMARY:Seminar Series in Quantitative Life Sciences and Medicine
URL:/qls/channels/event/seminar-series-quantitative-li
 fe-sciences-and-medicine-293724
END:VEVENT
END:VCALENDAR